(0.13%) 5 187.29 points
(0.30%) 38 969 points
(-0.14%) 16 327 points
(-0.68%) $77.95
(0.82%) $2.21
(-0.07%) $2 329.60
(0.21%) $27.67
(2.47%) $988.70
(-0.03%) $0.928
(0.47%) $10.88
(0.06%) $0.796
(0.18%) $91.51
0.77% £ 1 446.00
Live Chart Being Loaded With Signals
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders...
Stats | |
---|---|
Volumen de hoy | 137 294 |
Volumen promedio | 511 646 |
Capitalización de mercado | 1.96B |
EPS | £0 ( 2024-04-24 ) |
Próxima fecha de ganancias | ( £0 ) 2024-07-25 |
Last Dividend | £36.50 ( 2016-06-16 ) |
Next Dividend | £0 ( N/A ) |
P/E | 1 446.00 |
ATR14 | £1.191 (0.08%) |
Volumen Correlación
Indivior PLC Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Indivior PLC Correlación - Moneda/Commodity
Indivior PLC Finanzas
Annual | 2023 |
Ingresos: | £1.09B |
Beneficio Bruto: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2023 |
Ingresos: | £1.09B |
Beneficio Bruto: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2022 |
Ingresos: | £901.00M |
Beneficio Bruto: | £742.00M (82.35 %) |
EPS: | £-0.380 |
FY | 2021 |
Ingresos: | £791.00M |
Beneficio Bruto: | £664.00M (83.94 %) |
EPS: | £1.410 |
Financial Reports:
No articles found.
Indivior PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £10.40 | 2015-09-17 |
Last Dividend | £36.50 | 2016-06-16 |
Next Dividend | £0 | N/A |
Payout Date | 2016-07-29 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £46.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.12 | -- |
Div. Sustainability Score | 4.95 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.992 | -- |
Year | Amount | Yield |
---|---|---|
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £0 | 0.00% |
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SHOE.L | Dividend Knight | 2023-07-13 | Annually | 10 | 2.57% | |
IHG.L | Dividend Knight | 2023-08-31 | Annually | 21 | 1.16% | |
BMY.L | Dividend Knight | 2023-07-27 | Annually | 30 | 1.76% | |
OCN.L | Dividend Knight | 2023-05-18 | Annually | 19 | 3.96% | |
EPWN.L | Dividend Knight | 2023-09-28 | Annually | 11 | 2.16% | |
STM.L | Dividend Knight | 2023-08-31 | Semi-Annually | 17 | 2.49% | |
JLEN.L | Dividend King | 2023-08-31 | Quarterly | 11 | 366.93% | |
CAM.L | Dividend Junior | 2023-09-14 | Annually | 32 | 1.66% | |
PSHD.L | No Dividend Player | 2023-08-17 | Annually | 6 | 0.41% | |
GBG.L | Dividend Junior | 2023-06-22 | Annually | 22 | 0.51% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00183 | 1.500 | 9.96 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00102 | 1.200 | 9.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00542 | 1.500 | -1.051 | -1.576 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.968 | 0.800 | -0.161 | -0.129 | [1 - 3] |
quickRatioTTM | 0.526 | 0.800 | -1.609 | -1.287 | [0.8 - 2.5] |
cashRatioTTM | 0.242 | 1.500 | 9.77 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.144 | -1.500 | 7.59 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0.553 | 1.000 | -0.906 | -0.906 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -1.339 | -2.68 | [0 - 20] |
debtEquityRatioTTM | 0.215 | -1.500 | 9.14 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.830 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.616 | -1.616 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.117 | 1.000 | -7.32 | -7.32 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.60 | 7.68 | [0.5 - 2] |
Total Score | 4.95 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1 238.72 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00542 | 2.50 | -0.676 | -1.576 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -0.892 | -2.68 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.288 | 1.000 | -9.70 | 0 | [0.1 - 0.5] |
Total Score | -0.971 |
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico